Crizotinib

CD274 molecule ; Homo sapiens







9 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35110965 Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. 2022 1
2 35405360 Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. 2022 May 5
3 34428672 Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. 2021 Dec 1 1
4 32386255 Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. 2020 Aug 6
5 31098955 PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. 2019 Jun 2
6 28978110 Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment. 2017 Sep 15 1
7 27141355 Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. 2016 Mar 2
8 27141364 EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. 2016 Mar 3
9 27753543 STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. 2016 Dec 16 1